Dr. Stephen Hahn FDA hearing Dr. Stephen Hahn responds to a question on dairy labeling from Sen. Tammy Baldwin at his confirmation hearing, Nov. 20, 2019.
(Image by YouTube, Channel: National Milk Producers Federation) Details DMCA
Trump nominated Hahn last month to succeed former Commissioner Scott Gottlieb. National Cancer Institute Director Dr. Ned Sharpless and Department of Health and Human Services official Dr. Brett Giroir had been heading the FDA as acting commissioners.
New therapies for serious diseases will come under FDA review on Hahn’s watch. Following the presentation of positive data at recent American Society of Hematology meetings, Bristol-Myers Squibb seeks approval for two CAR-T cell therapies – lisocabtagene maraleucel in diffuse large B-cell lymphoma and idecabtagene vicleucel in multiple myeloma. Gilead Sciences said Wednesday that it had filed for approval of KTE-X19 in mantle cell lymphoma as well. Bluebird plans to initiate a rolling application for the gene therapy LentiGlobin in the blood disorder beta-thalassemia, which won European Medicines Agency approval earlier this year.